Level Four Advisory Services LLC Makes New $399,000 Investment in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Level Four Advisory Services LLC acquired a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,590 shares of the medical technology company’s stock, valued at approximately $399,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ATEC. BlackRock Inc. grew its position in Alphatec by 0.7% during the first quarter. BlackRock Inc. now owns 4,943,013 shares of the medical technology company’s stock worth $56,845,000 after buying an additional 34,257 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Alphatec by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,502,419 shares of the medical technology company’s stock valued at $30,612,000 after acquiring an additional 69,652 shares during the period. First Light Asset Management LLC grew its holdings in shares of Alphatec by 0.6% during the 1st quarter. First Light Asset Management LLC now owns 2,944,125 shares of the medical technology company’s stock worth $45,928,000 after purchasing an additional 17,952 shares in the last quarter. Millennium Management LLC increased its position in shares of Alphatec by 103.9% in the fourth quarter. Millennium Management LLC now owns 2,767,887 shares of the medical technology company’s stock worth $34,183,000 after purchasing an additional 1,410,693 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Alphatec by 30.5% in the fourth quarter. JPMorgan Chase & Co. now owns 2,071,701 shares of the medical technology company’s stock valued at $25,586,000 after purchasing an additional 483,935 shares in the last quarter. Institutional investors and hedge funds own 67.19% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ATEC. Morgan Stanley raised their target price on shares of Alphatec from $19.00 to $23.00 and gave the company an “overweight” rating in a report on Friday, August 4th. StockNews.com initiated coverage on shares of Alphatec in a research report on Thursday, August 17th. They set a “sell” rating for the company. Needham & Company LLC raised their target price on Alphatec from $19.00 to $20.00 and gave the company a “buy” rating in a report on Friday, August 4th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Friday, August 4th. Finally, Canaccord Genuity Group raised their price objective on Alphatec from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $13.46 on Monday. The stock has a market capitalization of $1.62 billion, a PE ratio of -8.91 and a beta of 1.27. Alphatec Holdings, Inc. has a one year low of $7.68 and a one year high of $19.14. The business’s fifty day moving average price is $16.09 and its 200-day moving average price is $15.80.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, August 3rd. The medical technology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.13). The business had revenue of $116.92 million during the quarter, compared to analyst estimates of $110.18 million. As a group, equities analysts expect that Alphatec Holdings, Inc. will post -1.39 EPS for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, Director David H. Mowry sold 9,500 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $14.46, for a total value of $137,370.00. Following the completion of the transaction, the director now owns 92,381 shares in the company, valued at $1,335,829.26. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director David H. Mowry sold 9,500 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $14.46, for a total transaction of $137,370.00. Following the sale, the director now directly owns 92,381 shares of the company’s stock, valued at $1,335,829.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Craig E. Hunsaker sold 6,542 shares of the firm’s stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $18.00, for a total transaction of $117,756.00. Following the completion of the sale, the executive vice president now owns 1,220,914 shares in the company, valued at approximately $21,976,452. The disclosure for this sale can be found here. Insiders sold 24,742 shares of company stock valued at $384,930 in the last 90 days. Insiders own 29.12% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization.